Principal Investigator
Matthew Schlumbrecht
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20240715
Clinical Trial Summary
A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
Phase
Phase II
Funding Agency/Sponsor
National Cooperative Group
Disease
Gynecologic Cancer
Contact Information
Phone Number
305-243-2647